SG11202100267TA - Solid forms of an azolopyrimidine compound - Google Patents

Solid forms of an azolopyrimidine compound

Info

Publication number
SG11202100267TA
SG11202100267TA SG11202100267TA SG11202100267TA SG11202100267TA SG 11202100267T A SG11202100267T A SG 11202100267TA SG 11202100267T A SG11202100267T A SG 11202100267TA SG 11202100267T A SG11202100267T A SG 11202100267TA SG 11202100267T A SG11202100267T A SG 11202100267TA
Authority
SG
Singapore
Prior art keywords
solid forms
azolopyrimidine
compound
azolopyrimidine compound
solid
Prior art date
Application number
SG11202100267TA
Inventor
Jenna Leigh Jeffrey
Manmohan Reddy Leleti
Dillon Harding Miles
Jay Patrick Powers
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of SG11202100267TA publication Critical patent/SG11202100267TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SG11202100267TA 2018-07-18 2019-07-17 Solid forms of an azolopyrimidine compound SG11202100267TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862700064P 2018-07-18 2018-07-18
PCT/US2019/042226 WO2020018680A1 (en) 2018-07-18 2019-07-17 Solid forms of an azolopyrimidine compound

Publications (1)

Publication Number Publication Date
SG11202100267TA true SG11202100267TA (en) 2021-02-25

Family

ID=69164033

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100267TA SG11202100267TA (en) 2018-07-18 2019-07-17 Solid forms of an azolopyrimidine compound

Country Status (10)

Country Link
US (1) US20210269422A1 (en)
EP (1) EP3823614A4 (en)
JP (1) JP2021531273A (en)
KR (1) KR20210033503A (en)
CN (1) CN113015523A (en)
AU (1) AU2019306582B2 (en)
CA (1) CA3106366A1 (en)
PH (1) PH12021550084A1 (en)
SG (1) SG11202100267TA (en)
WO (1) WO2020018680A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059142A1 (en) 2022-09-14 2024-03-21 Arcus Biosciences, Inc. Dispersions of etrumadenant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474599A (en) * 1982-07-14 1984-10-02 The Dow Chemical Company 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents
ES2295441T3 (en) * 2001-12-18 2008-04-16 MERCK & CO., INC. MODULATORS OF PIRAZOL HETEROARIL REPLACED 5 METABOTROPIC RECEIVER OF GLUTAMATE.
WO2010077582A1 (en) * 2008-12-16 2010-07-08 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
EP2900665B1 (en) * 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
MY184572A (en) * 2013-07-17 2021-04-05 Otsuka Pharma Co Ltd Cyanotriazole compounds
US10399962B2 (en) * 2017-01-20 2019-09-03 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders

Also Published As

Publication number Publication date
PH12021550084A1 (en) 2021-11-08
AU2019306582B2 (en) 2023-03-16
KR20210033503A (en) 2021-03-26
EP3823614A1 (en) 2021-05-26
US20210269422A1 (en) 2021-09-02
CA3106366A1 (en) 2020-01-23
WO2020018680A1 (en) 2020-01-23
EP3823614A4 (en) 2022-03-30
TW202011964A (en) 2020-04-01
CN113015523A (en) 2021-06-22
JP2021531273A (en) 2021-11-18
AU2019306582A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
GB201806578D0 (en) Novel compound
IL286218A (en) Solid state forms of ripretinib
GB201805174D0 (en) Compounds
GB201801355D0 (en) Compounds
IL280821A (en) Heterocyclic compound
ZA202101671B (en) Imidazopyridinone compound
IL276592A (en) Derivatives of sobetirome
GB201806072D0 (en) Methods of manufacture
ZA202104402B (en) Heterocyclic compound
IL263673A (en) Solid state forms of spiro-oxindole compounds
EP3894768C0 (en) Methods of cryo-curing
FI3810633T3 (en) Compounds
GB201805904D0 (en) Methods of Manufacture
SG11202100267TA (en) Solid forms of an azolopyrimidine compound
GB201803340D0 (en) Compounds
IL276107A (en) Solid forms of fasoracetam
SG11202105136WA (en) Application of chidamide
SG11202009356RA (en) Heterocyclic compound
GB201801128D0 (en) Compounds
GB201801130D0 (en) Compounds
IL283421A (en) Solid state forms of reproxalap
GB201910664D0 (en) Novel forms of compound
IL281637A (en) Synthetic method for the preparation of an hydrazine compound
IL277340A (en) Heterocyclic compound
PT3901141T (en) Novel form of isoquinolinesulfonamide